Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, pursuant to the Answer of 21 November 2016 to Question 53183, whether NHS England applied for an exemption from its legal requirement to make available ledipasvir-sofosbuvir (TA 363), ombitasvir-paritaprevir-ritonavir with or without ribavirin (TA 364) and daclastasvir (TA 365) within three months of the technology appraisal guidance being issued by NICE.

NHS England and the National Institute for Health and Care Excellence have advised that no extensions to the implementation period were requested as part of these technology appraisals.